Moderna said it is in talks with the FDA about Phase 4 Covid vaccine post-marketing data after regulators narrowed the label for the products last year. The company’s stated aim is to restore broader use once the additional real-world evidence is reviewed by U.S. regulators. The communications imply a continued regulatory focus on durability, effectiveness signal management, and population-level benefit-risk assumptions after label restrictions. Moderna’s discussions are part of a broader effort to align evidence generation with current FDA expectations for vaccine cohorts. For the market, the update matters because Moderna’s Covid assets remain tied to revenue optics while the company concurrently leans into oncology pipeline narratives. It also signals that “Phase 4” studies are being used as a mechanism to renegotiate clinical use scope. Investors and clinicians will likely watch how quickly Phase 4 evidence can translate into label changes and whether endpoints address the specific concerns behind the earlier FDA narrowing.